辅助化疗与靶向治疗在Ⅰ期肺腺癌术后患者中应用的研究进展  

Advances in the Application of Adjuvant Chemotherapy and Targeted Therapy in Postoperative Patients with StageⅠLung Adenocarcinoma

作　　者：赵珂 郭超[1] 陈野野[1] 李单青 Ke ZHAO;Chao GUO;Yeye CHEN;Shanqing LI(Department of Thoracic Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Science&Peking Union Medical College,Beijing 100730,China)

机构地区：[1]中国医学科学院北京协和医院胸外科,北京100730

出　　处：《中国肺癌杂志》2024年第10期777-784,共8页Chinese Journal of Lung Cancer

基　　金：中央高水平医院临床科研业务费(No.2022-PUMCH-B-011)资助。

摘　　要：肺癌是我国癌症负担和癌症死亡的主要原因之一,每年有近80万人新诊断为肺癌患者,其中接近一半的患者为肺腺癌(lung adenocarcinoma,LUAD)。根据目前的临床指南,手术是Ⅰ期LUAD患者的主要治疗手段,但是仅靠手术Ⅰ期LUAD患者的5年生存率仍不令人满意,为73%-90%,即有相当一部分患者需要其他手段来提高生存获益。化疗和靶向治疗已经在局部晚期和转移性LUAD患者的治疗中取得了巨大的成就,但是能否使Ⅰ期LUAD术后患者获益仍存在争议。基于该现状,已经有很多研究者关注到了这一问题并做出了有益的探索。本综述就影响Ⅰ期LUAD术后患者接受辅助化疗和靶向治疗的因素以及辅助化疗和靶向治疗在Ⅰ期LUAD术后患者中应用的相关临床研究作了简单的回顾,以期更广泛地了解该问题的最新进展并为推动该领域的持续研究寻找新的突破点。Lung cancer is one of the main causes of cancer burden and death in China,with nearly 800,000 newly diagnosed lung cancer patients each year,nearly half of whom are lung adenocarcinoma(LUAD)patients.According to current clinical guidelines,surgery is the main treatment for stageⅠLUAD patients,but the 5-year overall survival rate of stageⅠLUAD patients alone is still unsatisfactory,about 73%-90%,indicating that a considerable number of patients require other means to improve survival benefits.Chemotherapy and targeted therapy have achieved great success in the treatment of locally advanced and metastatic LUAD patients,but there is still controversy over whether they can benefit stageⅠLUAD postoperative patients.Under the circumstances,many researchers have paid attention to this issue and made beneficial explorations.This review provides a brief review of the factors that affect the acceptance of adjuvant chemotherapy and targeted therapy in stageⅠLUAD postoperative patients,as well as the relevant clinical research on the application of adjuvant chemotherapy and targeted therapy in stageⅠLUAD postoperative patients,in order to gain a broader understanding of the latest developments in this field and find new breakthroughs to promote sustained research in this field.

关 键 词：辅助治疗 化疗 靶向治疗 Ⅰ期 肺腺癌 

分 类 号：R734.2[医药卫生—肿瘤]